Castration or antiandrogen monotherapies remain options for prostate cancer treatment as only marginal benefits have been demonstrated with combined androgen blockade, although it may be that certain subgroups of patient may benefit. Of the nonsteroidal antiandrogens, bicalutamide 150 mg was as effective as castration in M0 patients with significant improvement in sexual interest and physical capacity, but the trial has yet to reach maturity. In M1 patients, bicalutamide 150 mg was not as effective as castration but this may be outweighed by symptomatic and quality of life benefits. Nilutamide is not recommended as monotherapy and there are little data on flutamide. The steroidal antiandrogen, cyproterone acetate, is as effective as oestrogen therapy and has a better side-effect profile, although cardiovascular and hepatic side effects are still of concern. Compared with flutamide, in a recently completed EORTC study, side effects such as gynaecomastia, diarrhoea, nausea, and liver function deterioration occurred less often, and thrombotic effects more often, in the cyproterone acetate group. No difference was seen in the preservation of sexual functioning. Quality of life issues are becoming increasingly important and thus antiandrogen monotherapy may become more widely used in the management of prostate cancer.

Keywords:
Antiandrogens, Monotherapy, Bicalutamide, Prostate cancer
1.
Prostate Cancer Trialists’ Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265–269.
2.
Eisenberger M, Crawford ED, McLeod D, Loehrer P, Wilding G, Blumenstein B: A comparison of bilateral orchiectomy (orch) with or without flutamide in stage D2 prostate cancer (PC) (NCI INT-0105 SWOG/ECOG). 33rd Annual Meeting of the American Society of Clinical Oncology (ASCO) 1997:A1311.
3.
Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419–424.
4.
Bales GT, Chodak GW: A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996;47(suppl 1A):38–43.
5.
Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Blackledge GRP: ‘Casodex’ (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer: results from two multicentre randomized trials at median follow-up of 4 years. Urology 1998;51:389–396.
6.
Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G: A randomised comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; in press.
7.
Tyrrell CJ: Tolerability and quality of life aspects with the antiandrogen Casodex (ICI 176, 334) as monotherapy for prostate cancer. International Casodex investigators. Eur Urol 1994;26(suppl 1):15–19.
8.
Jacobo E, Schmidt JD, Weinstein SH, Flocks RH: Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology 1976;8:231–233.
9.
Neri RO, Kassem NY: Biological and clinical properties of antiandrogens. Prog Cancer Res Ther 1984;31:507–518.
10.
Lund F, Rasmussen F: Flutamide versus stilboestrol in the management of advanced prostatic cancer: A controlled prospective study. Br J Urol 1988;61:140–142.
11.
Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, Trump D: Double blind randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996;14:2250–2257.
12.
Johansson JE, Andersson SO, Beckman KW, Lingardh G, Zador G: Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. Urology 1987;29:55–59.
13.
Boccon-Gibod L, Fournier G, Bottet P, Maréchal JM, Guiter J, Rischmann P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE: Flutamide versus orchidectomy in patients with metastatic prostate carcinoma. Eur Urol 1997;32:391–395.
14.
Pavone-Macaluso M: Flutamide monotherapy versus combined androgen blockade in advanced prostate cancer. Interim report of an Italian multicenter, randomised study. 23rd Congress of the Société Internationale d’Urologie (SIU) 1994, A354.
15.
Boccon-Gibod L: Are non-steroidal antiandrogens appropriate as monotherapy in advanced prostate cancer? Eur Urol 1998;33:159–164.
16.
Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R: Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advance prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986;136:624–631.
17.
De Voogt HJ, Smith PhH, Pavone-Macaluso M, de Pauw M, Suciu S, on behalf of the EORTC-GU Group: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762. J Urol 1986;135:303–307.
18.
Schröder FH, Whelan P, Kurth R, Sylvester R, de Pauw M and members of the EORTC Genitourinary Group: Antiandrogens as monotherapy for metastatic prostate cancer: A preliminary report on EORTC protocol 30892; in Schröder FH (ed): Recent advances in prostate cancer. London, Parthenon, 1997, pp 141–146.
19.
Ellis WJ, Grayhack JT: Sexual function in aging males after orchiectomy and estrogen therapy. J Urol 1963;89:895–899.
20.
Pollack A, Zagars GK: Androgen ablation in addition to radiation therapy for prostate cancer: Is there a true benefit? Semin Radiat Oncol 1998;8:95–106.
21.
Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.